Medicare has fixed a new government price for a second group of major prescription drugs, but the household consequence remains one plan year away. The 15 maximum fair prices begin in 2027 and include the product group containing Ozempic, Rybelsus and Wegovy. That official price can lower the amount moving through Part D, yet it is not a universal copayment and does not override the coverage rules attached to each product.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
CMS has completed the second negotiation cycle
The current CMS negotiated-price record lists 15 Part D drugs for the 2027 price year and identifies agreements with their manufacturers. These are completed maximum fair prices, not forecasts or opening offers. Combined with the first 10 drugs whose prices began in 2026, the second cycle will bring 25 products under negotiated pricing. The published file also supplies the unit and package prices used across the Part D claims chain.
CMS groups products by active ingredient and manufacturer for negotiation, which is why Ozempic appears with Rybelsus and Wegovy. The grouping does not make the products clinically interchangeable. Their dosage forms, approved uses and covered presentations differ, and the 2027 CMS fact sheet reports unit and package details that matter when translating a negotiated amount into a claim.
The effective date separates current fact from future benefit. A prescription filled during 2026 remains governed by the 2026 plan and price structure, even though CMS has published the following year’s maximum. The negotiation announcement can inform fall plan selection, but it does not retroactively reduce a pharmacy charge or guarantee that an existing 2026 copayment will change.
A maximum fair price is not the amount every member pays
The negotiated figure governs the price manufacturers must make available for eligible Medicare transactions. A beneficiary’s bill still emerges from the Part D deductible, the plan’s copayment or coinsurance design, Extra Help status and the pharmacy network. A member owing percentage coinsurance may feel a price reduction differently from a member assigned a fixed copayment. Plan benefit design remains the last step between the program price and the member’s cost.
Formulary obligations do not erase utilization management. Plans can still apply prior authorization, step therapy and quantity limits within Medicare rules, and the dispensed presentation must match what the program covers. A lower program price therefore answers the cost of an approved claim; it does not establish that a particular prescription or indication has been approved. CMS formulary review remains the enforcement mechanism for access requirements tied to selected drugs.
The Ozempic group makes that boundary especially visible. Medicare can cover GLP-1 drugs for certain medically accepted indications, while federal law continues to restrict coverage when a drug is used only for weight loss. Negotiation changes the price of covered use, not the underlying statutory line between covered and excluded treatment. FDA-approved indications and Medicare’s coverage statute continue to govern that boundary in 2027.
The 2027 plan comparison will reveal the household result
CMS estimated substantial aggregate savings from the second-cycle agreements in its official price announcement. Aggregate program savings and individual out-of-pocket savings are not the same measure. The latter depends on whether the member uses a selected drug, whether the plan covers the exact prescription and how the plan translates the negotiated price into cost sharing. CMS calculates its estimates against historical net spending rather than a single beneficiary’s receipt.
Annual plan notices and the 2027 Medicare Plan Finder will provide the missing member-level information. A useful comparison requires the exact drug name, dose, package and frequency because a broad product label can conceal different presentations. The negotiated price is a firm input to that comparison, while the plan’s formulary and benefit design determine the output. Those materials will also expose pharmacy and utilization rules that CMS’ price file cannot show.
The second cycle is final enough to reshape Medicare drug spending but still incomplete as a household budget. CMS has established what participating manufacturers must make available starting in 2027. Only the next plan year’s coverage documents will show whether that change appears as a lower copayment, reduced coinsurance or primarily as savings elsewhere in the Part D system.
This article was created with AI assistance and reviewed for accuracy against current CMS records.
More Financial Reading
